- Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).Zhao, Hong; Zhou, Aiping; Tu, Jianfei; Bai, Yuxian; Mao, Xianhai; Song, Tianqiang; Li, Bo; Dai, Wenxiang; Lv, Jing; Wang, Jufeng; Che, Xu; Liu, Lianxin; Zhang, Lianhai; Wu, Wei; Cai, JianqiangAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- A phase II study combining KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): Updated efficacy and safety results.Xing, Baocai; Da, Xu; Zhang, Yanqiao; Ma, YueAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 1
- Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 studyQin, Shukui; Chen, Zhendong; Fang, Weijia; Ren, Zhenggang; Xu, Ruocai; Ryoo, Baek-Yeol; Meng, Zhiqiang; Bai, Yuxian; Chen, Xiaoming; Liu, Xiufeng; Xiao, Juxiang; Ho, Gwo Fuang; Mao, Yimin; Ye, Xing; Ying, Jieer; Li, Jianfeng; Zhong, Wen Yan; Zhou, Yu; Siegel, Abby B.; Hao, ChunyiASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 2022-01-20 To 2022-01-22.被引 73
会议论文
Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.
3被引9阅读
